ZIKAlliance

ZIKAlliance
Name	ZIKAlliance
Formation	2015
Type	Research consortium
Headquarters	Bogotá
Region served	Latin America, Caribbean
Leader title	Coordinating PI

ZIKAlliance

ZIKAlliance is a multicenter research consortium formed to investigate the emergence, transmission, clinical manifestations, and public health implications of Zika virus-related disease across Latin America and the Caribbean. The consortium brought together academic institutions, public health agencies, and clinical networks to conduct prospective cohort studies, case-control investigations, and laboratory research during the 2015–2017 Zika virus epidemic. Its work intersected with regional public health responses, international research programs, and clinical networks to generate evidence on congenital infection, neurological complications, and vector ecology.

Background

ZIKAlliance was established in the immediate aftermath of the 2015 Zika virus outbreak first widely recognized in Brazil and associated with clusters in Northeastern Brazil, northern Colombia, and islands in the Pacific. The consortium formed amidst coordinated responses involving World Health Organization, Pan American Health Organization, Oswaldo Cruz Foundation, Fiocruz, Centers for Disease Control and Prevention, and national ministries such as Brazil's Ministry of Health (Brazil), Colombia's Ministry of Health and Social Protection, and Puerto Rico's Department of Health (Puerto Rico). The initiative aligned with research priorities articulated by Wellcome Trust, Bill & Melinda Gates Foundation, and regional research networks such as Latin American Society for Pediatric Infectious Diseases and Clinical Trials Network. Members aimed to address gaps identified after prior work by groups at Universidade Federal de Pernambuco, Universidade de São Paulo, Instituto Nacional de Salud (Colombia), and university hospitals in Bogotá, Recife, Rio de Janeiro, and Manaus.

Organization and Membership

The consortium was coordinated by principal investigators drawn from university research centers and public health institutes across countries including Brazil, Colombia, Ecuador, Peru, Panama, Honduras, and Puerto Rico. Institutional partners included research universities such as Universidade Estadual de Campinas, Pontifícia Universidade Católica do Rio Grande do Sul, Universidad Nacional de Colombia, Universidad San Francisco de Quito, and clinical hospitals like Hospital das Clínicas da Faculdade de Medicina da USP and Instituto Materno Infantil. International collaborators involved academic centers from United Kingdom universities, United States medical schools, and European public health institutes such as Institut Pasteur, London School of Hygiene & Tropical Medicine, and Karolinska Institutet. The consortium governance included steering committees, scientific advisory boards with specialists in neonatology, neurology, virology, and epidemiology from institutions such as Johns Hopkins University, Harvard T.H. Chan School of Public Health, and McGill University.

Research Objectives and Activities

ZIKAlliance pursued objectives covering clinical characterization of congenital Zika syndrome, incidence estimation of neurological outcomes in adults, development and validation of diagnostic assays, and evaluation of vector control implications. Activities included prospective pregnancy cohorts to document fetal outcomes, pediatric follow-up clinics to assess neurodevelopment, case-control studies of Guillain–Barré syndrome coordinated with neurologists from referral centers, and laboratory efforts to refine serology and molecular diagnostics using protocols from World Health Organization and Pan American Health Organization. The consortium worked with translational groups at Evandro Chagas Institute and Institut Pasteur de Guyane to sequence viral genomes and link phylogenetics to epidemiologic patterns identified in collaborations with the Global Initiative on Sharing All Influenza Data community and national reference laboratories.

Field Studies and Surveillance

Field operations integrated active surveillance networks in urban and peri-urban sites including Recife, Salvador, Belo Horizonte, Medellín, Quito, and Caribbean islands. Teams deployed standardized clinical case report forms, ultrasound monitoring protocols used in maternal–fetal medicine centers, and entomological surveys coordinated with vector control units in municipalities. Surveillance linkages connected to hospital networks such as Instituto Nacional de Salud Pública (México) and sentinel systems managed by national institutes to detect clusters of microcephaly, rash illness, and neurological syndromes. Entomology teams sampled Aedes aegypti populations and collaborated with laboratories performing vector competence assays at institutes like Fiocruz Amazônia.

Findings and Impact

Consortium outputs contributed to delineation of risk windows for congenital infection, characterization of craniofacial and neurologic phenotypes linked to prenatal exposure, and quantification of absolute risks for adverse pregnancy outcomes in different gestational periods. Findings informed clinical guidelines issued by professional bodies including American College of Obstetricians and Gynecologists, Brazilian Society of Pediatrics, and national obstetrics societies, and supported policy decisions by Ministry of Health (Brazil) and Ministry of Health and Social Protection (Colombia). Phylogenetic analyses traced regional Zika virus transmission pathways overlapping with travel corridors involving Caribbean and South American hubs, influencing surveillance priorities at ports of entry and airport screening programs used by public health agencies. Publications from consortium investigators appeared in journals and were cited by guideline committees and global health funders guiding research funding streams.

Funding and Governance

Funding for the consortium combined grants and in-kind contributions from international funders such as Wellcome Trust, European Commission Horizon 2020, Bill & Melinda Gates Foundation, and national research councils including FAPESP and Colciencias. Governance structures featured memorandum of understanding agreements among partner institutions, data sharing policies negotiated with national reference laboratories, and ethical oversight from institutional review boards at participating universities and hospitals, including committees at Universidade de São Paulo and Universidad Nacional de Colombia. The consortium maintained collaborations with regulatory agencies and donor organizations to transition research findings into public health action and capacity-building initiatives across partner sites.

Category:Public health consortia